Ionis Pharmaceuticals Stock Today
| IONS Stock | USD 32.91 0.18 0.55% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Ionis Pharmaceuticals is selling for under 32.91 as of the 21st of March 2025; that is 0.55 percent increase since the beginning of the trading day. The stock's lowest day price was 32.3. Ionis Pharmaceuticals has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of May 1991 | Category Healthcare | Classification Health Care |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Ionis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 158.96 M outstanding shares of which 12.67 M shares are currently shorted by private and institutional investors with about 7.45 trading days to cover. More on Ionis Pharmaceuticals
Moving together with Ionis Stock
Moving against Ionis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Ionis Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Stanley Crooke | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Dow Jones Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Excise Tax Activities | Animal Testing | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIonis Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ionis Pharmaceuticals' financial leverage. It provides some insight into what part of Ionis Pharmaceuticals' total assets is financed by creditors.
| |||||
Ionis Pharmaceuticals (IONS) is traded on NASDAQ Exchange in USA. It is located in 2855 Gazelle Court, Carlsbad, CA, United States, 92010 and employs 1,069 people. Ionis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.2 B. Ionis Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 158.96 M outstanding shares of which 12.67 M shares are currently shorted by private and institutional investors with about 7.45 trading days to cover.
Ionis Pharmaceuticals currently holds about 2.04 B in cash with (500.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.36.
Check Ionis Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Ionis Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ionis Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ionis Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ionis Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Ionis Ownership Details
Ionis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 2.7 M | |
| Citadel Advisors Llc | 2024-12-31 | 2.2 M | |
| Deep Track Capital, Lp | 2024-12-31 | 1.9 M | |
| Ubs Group Ag | 2024-12-31 | 1.9 M | |
| Macquarie Group Ltd | 2024-12-31 | 1.8 M | |
| Norges Bank | 2024-12-31 | 1.7 M | |
| Clearbridge Advisors, Llc | 2024-12-31 | 1.6 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.5 M | |
| Two Sigma Advisers, Llc | 2024-12-31 | 1.3 M | |
| Fmr Inc | 2024-12-31 | 22.7 M | |
| Vanguard Group Inc | 2024-12-31 | 16.5 M |
Ionis Pharmaceuticals Historical Income Statement
Ionis Stock Against Markets
Ionis Pharmaceuticals Corporate Management
| Brett Monia | Sr. VP of Drug Discovery and Corporate Devel. | Profile | |
| Patrick Esq | Chief VP | Profile | |
| Eric Swayze | Executive Research | Profile | |
| Hayley Soffer | Vice Communications | Profile |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.